Allogeneic bone marrow transplantation has been accepted as a powerful therapeutic modality to overcome for successfull clinical reuslts in malignant hematologic disease and severe aplastic anemia in spite of various barriers. We analysed 62 patients who had been admitted to Catholic BMT Center and have performed since malignant hematologic disesaes and severe aplastic anemia were determined to be the subject of National Public Health Care Program(between Oct. l992 and Mar. 1995). Number of patients with acute myelogenous leukemia(AML), acute lymphoblastic leukemia(ALL), chronic myelogenous leukemia(CML) and severe aplastic anemia(SAA) were 17, 4, 21, 20 respectively. We have used pretransplant conditionig regimens which were consisted of total body irradiation(TBI, fractionated 1320 cGy) and cyclophosphamide(CY, 120mg/kg) in leukemic disease(39/42) and anti-thymocyte globulin(ATG, 1.5 vial/10kg, Pasteur Merieux), CY(200mg/kg) and procar- baziine(6.25 mg/kg for 6 days, rutulard, Roche) in SAA(17/20). Cyclosporin A and short course methotrexate were used to prevent graft-versus-host disease(GVHD). Disease-free overall survival rate was 71% in aute leukemia, 67% in CML and 85% in SAA respectively. Maior complications were acute GVHD<35% grade I-IV among them, grade III-IV 14.5%),CMV antigenemia(l1.2%), herpes zoster(9.6%), veno-occlussive disease(8%), TTP-like syndrome(4.8%), chronic GVHD(3%) and interstitial pneumonia(1.6%). Major causes of death were leukemic relapse(9.7%), primary engraftment failure/rejection(6.5%), acute GVHD(3%) and TTP-like syndrome(3%). We suggest again that allogeneic BMT should be considered as the effective therapeutic modality to cure malignant hematologic diseases and aplastic anemia. For the purpose of obtaining better clinical outcome of allogeneic BMT, it should be early performed as soon as possible in clinial course.
PDF Links
Full text via DOI 
Download Citation 
